ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptimmune Therapeutics PLC
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Adaptimmune Therapeutics PLC revenue by segment
By business segment
By product or service
| Revenue | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $11.08M | $4.05M | – | – | – | – | – | – | – | – | – | – | 81.0% | – |
| Development revenue | $2.60M | $3.24M | $1.99M | $40.90M | $128.23M | $5.68M | $231.00K | $7.32M | $5.13M | $47.60M | $11.03M | $7.01M | 19.0% | -98.0% |
| Commercial Sales | – | – | – | $0 | – | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Adaptimmune Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.